RNA News
Archived Headlines
- Muscle disorder biotech Avidity Biosciences sets terms for $150 million IPO 06/08/20
- US IPO Week Ahead: AZEK and Vroom take the lead in another 8 IPO week 06/05/20
- Muscle disorder biotech Avidity Biosciences files for a $100 million IPO 05/26/20
- US IPO Weekly Recap: The IPO market picks up before Memorial Day 05/22/20
US IPO Weekly Recap: Vroom soars in another 8 IPO week
Eight IPOs and one SPAC entered the public markets this past week led by Vroom (VRM), which popped 118% in ...read more
Avidity Biosciences prices further upsized IPO at $18, the high end of the upwardly revised range
Avidity Biosciences, a preclinical biotech developing antibody therapies for muscle disorders, raised $259 million by offering 14.4 million shares at $18, the high end of the upwardly revised range of $17 to $18. Earlier on Thursday, the La Jolla, CA-based...read more
Muscle disorder biotech Avidity Biosciences increases proposed IPO deal size by 40%
Avidity Biosciences, a preclinical biotech developing antibody therapies for muscle disorders, raised the proposed deal size for its upcoming IPO on Thursday. The La Jolla, CA-based company now plans to raise $210 million by offering 12 million shares at a...read more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more